[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sichuan Academy of Medical Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":205},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,71,99,125,155,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644833","evaluate-the-effect-of-remote-exercise-intervention-on-blood-glucose-control-and-physical-fitness-in-t2dm-patients-100644833",false,"NCT07676773","Evaluate the Effect of Remote Exercise Intervention on Blood Glucose Control and Physical Fitness in T2DM Patients","A 12 Weeks Clinical Trail to Evaluate the Effect of Remote Exercise Intervention on Blood Glucose Control and Physical Fitness in T2DM Patients","Inclusion Criteria:\n\n(1) Both gender, age from 40 to 69 years old. (2) Meeting the diagnostic criteria for type 2 diabetes in China. (3) HbA1c is within 6.5%-7 .0% and no medication is taken. (4) Newly diagnosed with diabetes or the duration of the disease is no more than 5 years. (5) Possessing general exercise capacity and no obvious diseases in the muscle and osteoarticular systems. (6) The exercise risk is evaluated as medium or low risk through the PAR-Q+ questionnaire. (7) No contraindications to exercise tests. (8) Willing to adopt intensifed lifestyle intervention and complete the entire research process.\n\nExclusion Criteria:\n\n(1) T1DM patients, autoimmune diabetes and special types of diabetes, including hypercortisolism, growth hormone tumor, glucagonoma and some special types of diabetes caused by genetic factors; (2) pregnant or lactating women; (3) regular use of antidiabetic drugs or insulin in the past three months; (4) fasting blood glucose level \\> 16.7 mmol\u002FL; (5) recurrent hypoglycemia; (6) a history of acute diabetic complications, including diabetic ketoacidosis, hyperosmolar hyperglycemia, and lactic acidosis; (7) a history of severe chronic microvascular or macrovascular complications; (8) diseases that may be exacerbated by exercise or impair exercise efciency, such as uncontrolled hypertension, hyperthyroidism, osteoarthritis or hypokalemia; (9) unable to use smart phones or wearable smart devices independently; (10) communication or motor dysfunction; (11) Patients with severe chronic diseases could not participate in the study.",true,"ALL","18 Years","69 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","The intervention group received 12 weeks of continuous remote intervention combined with health education. The control group only received 12 weeks of continuous health education, and the content and frequency were the same as those of the management group. Both groups received instruction at the beginning of the intervention. The intervention group was given priority to continuous walking\u002Frunning combined with aerobic exercise and swimming. Five to seven sessions per week for 45 minutes each session. Acclimatizations were performed at an intensity of 40%-49% reserve oxygen uptake (VO2R) from weeks 1 to 4, and exercise was performed at an intensity of 50%-59% VO2R from weeks 5 to 12. 5 minutes each of preparation and grooming activities (including joint movement and stretching) for each exercise. Combined with incremental load resistance exercise 2-3 times a week, 8 movements, 2-3 groups each time, repeated 8-10 times\u002Fgroup, with a 2-min rest between groups. The heart rate, RPE (12-13, \"fairly easy\" to \"somewhat laborious\") and exercise bracelet were used to monitor the intensity and amount of exercise. The exercise intervention was usually delivered 1-2 h after a meal. The daily medical supervision in the process of management implementation was carried out by trained sports managers through the doctor terminal of \"exercise assistant\" to collect and monitor the data of the study subjects.",[28,29],"Diabete Type 2","Cardio Respiratory Fitness",[31,32,33,34,35],"Type 2 diabetes mellitus","Integration of sports and healthcare","Randomized controlled trial","Exercise prescription","Remote exercise intervention","RECRUITING","2026-06-24",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":40},"2026-06-01",{"date":44,"type":22},"2026-12-31",{"name":46,"class":47},"Sichuan Academy of Medical Sciences","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":48},"100644550","effect-of-notch2nlc-gene-variations-on-niid-clinical-features-100644550","NCT07670169","Effect of NOTCH2NLC Gene Variations on NIID Clinical Features","NOTCH2NLC-NIID","Inclusion Criteria:\n\n* Member of a single family (pedigree) with known NOTCH2NLC-related neuronal intranuclear inclusion disease (NIID), including clinically diagnosed patients, asymptomatic GGC repeat expansion carriers, and healthy relatives without the expansion.\n* Age 18 to 85 years at the time of enrollment.\n* Able and willing to undergo genetic testing for NOTCH2NLC (including long-read sequencing) and a skin punch biopsy.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Unstable vital signs or any acute medical condition that would interfere with study participation.\n* Any condition that, in the opinion of the investigator, makes the participant unsuitable for the study.",{"count":57,"type":22},12,"OBSERVATIONAL","This study aims to understand how differences in the NOTCH2NLC gene affect the symptoms and course of neuronal intranuclear inclusion disease (NIID), a rare inherited neurological disorder. NIID is caused by an abnormal expansion of a GGC DNA repeat in the NOTCH2NLC gene, but members of the same family can have very different repeat sizes and patterns, leading to a wide variety of problems-such as difficulties with memory, movement, sensation, or involuntary body functions. The main goal is to uncover how these genetic differences (repeat length and interruption pattern) contribute to the severity and type of symptoms.\n\nThe study is being conducted at Sichuan Provincial People's Hospital and will enroll approximately 12 individuals from a single family, including those diagnosed with NIID, family members who carry the genetic change but are not yet sick, and healthy relatives. Participants must be 18-85 years old, able to complete genetic testing and a small skin biopsy, and willing to provide informed consent. Those who are medically unstable or otherwise unable to participate will not be enrolled.\n\nThe study has both a retrospective part (collecting past medical records) and a prospective follow-up. At the beginning, all participants will have a physical exam, provide a blood sample (for long-read DNA sequencing and RNA sequencing), and undergo a 3-mm skin biopsy to look for disease-related protein deposits. Brain MRI and nerve\u002Fmuscle electrical tests will also be performed if not done recently. After this baseline visit, everyone will be followed every 6 months for a total of 2 years (5 visits total). Each follow-up visit includes assessments of thinking, memory, movement, autonomic function, pain, and quality of life, along with a neurological exam and repeat imaging\u002Felectrical tests as needed. At the final 24-month visit, another blood sample will be taken for RNA sequencing to see how gene activity changes over time.\n\nThis is an observational study; there is no experimental treatment. Participants will be compensated a total of ¥3,000 across all visits for their time and travel. All data and samples will stay in China and will not be shared internationally.",[61],"Neuronal Intranuclear Inclusion Disease (NIID)",[63],"NIID, NOTCH2NLC, GGC repeat expansion",{"date":65,"type":40},"2026-06-26",{"date":67,"type":40},"2026-04-01",{"date":69,"type":22},"2029-02-01",{"name":46,"class":47},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100629140","phase-4-early-dexmedetomidine-and-sympathetic-regulation-in-sepsis-100629140","NCT07470775","Early Dexmedetomidine and Sympathetic Regulation in Sepsis","A Prospective Study on the Effects of Early Dexmedetomidine Administration on Sympathetic Nervous System Activity, Pathophysiological Mechanisms, and Clinical Outcomes in Sepsis","DEX-SNS-SEPSIS","Inclusion Criteria:\n\nAge ≥ 18 year Septic shock defined by Sepsis-3 criteria Enrollment within 24 hours of diagnosis APACHE II score \\> 10\n\nExclusion Criteria:\n\nPregnancy or lactation Second- or third-degree atrioventricular block Persistent bradycardia (HR \\\u003C50 bpm) requiring intervention Hypersensitivity to dexmedetomidine Norepinephrine dose \\>0.5 μg\u002Fkg\u002Fmin End-stage disease or life expectancy \\\u003C72 hours Any condition deemed unsuitable by the investigator",{"count":80,"type":22},168,[82],"PHASE4","The goal of this clinical trial is to learn whether early administration of dexmedetomidine can improve autonomic nervous system regulation and clinical outcomes in adult patients with septic shock. It will also evaluate the safety of dexmedetomidine in this population.\n\nThe main questions it aims to answer are:\n\nDoes early dexmedetomidine improve sympathetic nervous system activity, as measured by heart rate variability (HRV) and blood pressure variability (BPV)?\n\nDoes dexmedetomidine reduce endogenous catecholamine levels and vasopressor requirements?\n\nDoes early autonomic modulation improve organ function and survival outcomes in septic shock? Researchers will compare dexmedetomidine to a placebo (normal saline) to determine whether dexmedetomidine improves hemodynamic stability and prognosis in patients with septic shock.\n\nParticipants will:\n\nBe randomly assigned to receive dexmedetomidine (0.5 μg\u002Fkg\u002Fh) or placebo by continuous intravenous infusion for 48 hours\n\nUndergo continuous ECG and invasive blood pressure monitoring\n\nHave blood samples collected at predefined time points to measure inflammatory markers and endogenous catecholamine levels\n\nBe assessed for organ function, vasopressor use, and perfusion parameters during the first 48 hours\n\nBe followed up for 28-day and 90-day survival outcomes",[85,86],"Sepsis","Septic Shock",[88,89,86],"Dexmedetomidine","Sympathetic Nervous System","NOT_YET_RECRUITING","2026-03-10",{"date":93,"type":40},"2026-03-13",{"date":95,"type":22},"2026-03-01",{"date":97,"type":22},"2028-03-01",{"name":46,"class":47},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100613209","phase-2-a-multicenter-clinical-trial-evaluating-the-efficacy-and-safety-of-taurine-as-an-adjunctive-therapy-in-multiple-sclerosis-100613209","NCT07263607","A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis","A Multicenter Clinical Study on Taurine Treatment for Multiple Sclerosis","Inclusion Criteria:\n\n* 1.Age and Gender: Male or female participants aged 18 to 65 years.\n* 2.Diagnosis: Patients diagnosed with multiple sclerosis (MS) according to the 2017 revised McDonald criteria.\n* 3.Treatment Background: Patients receiving stable disease-modifying therapy (DMT) prior to enrollment.\n* 4\\. EDSS score between 1.0 and 5.5 at screening.\n* 5\\. Compliance: Ability and willingness to comply with all study procedures, follow-up visits, and study medication requirements.\n* 6.Informed Consent: Participants must provide written informed consent before any study-specific procedures are performed.\n* 7 Female participants must be non-pregnant and non-lactating, or, if of childbearing potential, must agree to use effective contraception during the study\n\nExclusion Criteria:\n\n* 1\\. Patients with known hypersensitivity to taurine or any of its components\n* 2\\. Women who are pregnant or breastfeeding\n* 3\\. Patients currently participating in other clinical trials\n* 4\\. Patients who refuse to participate in the relevant clinical study","65 Years",{"count":21,"type":22},[109],"PHASE2","This multicenter, randomized, open-label clinical trial aims to evaluate the efficacy and safety of taurine as an adjunctive therapy to standard disease-modifying treatments (DMTs) in patients with multiple sclerosis (MS). The study seeks to determine whether oral taurine can reduce the number and volume of new or enlarging MRI lesions, decrease relapse rates, and slow disability progression as measured by the Expanded Disability Status Scale (EDSS). It will also explore the effects of taurine on gut microbiota composition, serum neurodegeneration biomarkers (GFAP and NfL), and cognitive function assessed by MMSE and MoCA. Approximately 80 eligible participants will be enrolled and randomly assigned to either continue standard DMT therapy or receive taurine supplementation in addition to DMTs. The treatment duration will be 24 months, with follow-up visits every 3 months for clinical assessment, blood and stool sample collection, and MRI scans every 6 months. This study aims to provide new clinical evidence supporting taurine as a safe and potentially beneficial adjunctive therapy for multiple sclerosis.",[112],"Multiple Sclerosis (MS) Relapsing Remitting",[114,115,116],"multiple sclerosis","taurine","multicenter, randomized, open-label clinical trial","2025-11-24",{"date":119,"type":40},"2025-12-04",{"date":121,"type":22},"2026-01-01",{"date":123,"type":22},"2029-11",{"name":46,"class":47},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100608227","early-phase-1-a-preliminary-exploratory-clinical-trial-to-evaluate-the-efficacy-of-npdr-01-eye-drops-in-the-treatment-of-non-proliferative-diabetic-retinopathy-100608227","NCT07198815","A Preliminary Exploratory Clinical Trial to Evaluate the Efficacy of NPDR-01 Eye Drops in the Treatment of Non-Proliferative Diabetic Retinopathy","Inclusion Criteria:\n\n1.1. Patients aged 18 to 75 years diagnosed with type 1 or type 2 diabetes mellitus, with non-proliferative diabetic retinopathy (NPDR) confirmed by a qualified ophthalmologist. NPDR diagnosis must be based on current standard fundus examination or retinal photography and should meet the International Clinical Diabetic Retinopathy Disease Severity Scale, with the presence of microaneurysms.\n\n1.2. Willing and able to comply with study procedures and provide informed consent: Subjects must voluntarily participate in the study, sign the informed consent form, and fully understand the study objectives, potential drug risks, and research procedures. There should be no other ocular diseases causing retinal neovascularization.\n\n1.3. No known significant media opacities that would interfere with fundus image acquisition.\n\n1.4. No history of retinal laser photocoagulation, and no anticipated laser treatment within the next 6 months.\n\n1.5. No history of intravitreal injection therapies, and no anticipated intravitreal treatments within the next 6 months.\n\n1.6. No diabetic macular edema (DME) as defined by central retinal thickness on OCT: \\\u003C290 μm for females and \\\u003C305 μm for males (or \\\u003C305 μm for females and \\\u003C320 μm for males, depending on the criteria used).\n\n1.7. Clinical fundus examination and ultra-widefield retinal photography show DR changes milder than early proliferative DR (PDR).\n\n1.8. No history of ocular surgery. 1.9. Diabetes history: Duration of diabetes ≥ 1 year; glycemic control with HbA1c ≤ 10%.\n\n1.10. Visual acuity requirement: Best-corrected visual acuity (BCVA) must be better than 20\u002F400, to ensure reliable assessment of drug efficacy.\n\nExclusion Criteria:\n\n2.1. Age Restrictions: Subjects younger than 35 years or older than 75 years. 2.2. Severe Ocular Complications: Subjects whose diabetic retinopathy has progressed to proliferative diabetic retinopathy (PDR) or who present with clinically significant macular edema (CSME). This includes vitreous hemorrhage, retinal detachment, or other acute complications. Also excluded are subjects with severe optic nerve damage or glaucoma (intraocular pressure \\> 21 mmHg).\n\n2.3. Poor Diabetes Control: Subjects with HbA1c \\> 10%, or with highly fluctuating blood glucose levels that may interfere with efficacy evaluation.\n\n2.4. Other Ocular Diseases: Presence of age-related macular degeneration (AMD), retinal vascular occlusion, retinal infections, or other significant ocular pathologies. Also excluded are those with corneal diseases, severe conjunctivitis, or dry eye syndrome that may affect topical ocular drug administration.\n\n2.5. History of Ocular Surgery or Treatments: Subjects who received intraocular injections (e.g., anti-VEGF agents) or retinal laser therapy within the past 6 months. Also excluded are those who recently underwent cataract surgery or other retinal-related surgeries.\n\n2.6. Other Health Conditions: Subjects with abnormal liver function, disorders in ketone body metabolism, or those with serious systemic diseases that may interfere with treatment (e.g., acute heart disease, liver disease, renal failure). History of cancer or current malignancy, or any major illness affecting drug metabolism or immune function.\n\n2.7. Drug Allergy History: Known allergy or hypersensitivity to the study drug or any of its components (e.g., drug carriers, excipients).\n\n2.8. Concomitant Medications: Use of antiplatelet agents (e.g., aspirin, clopidogrel) or anticoagulants (e.g., warfarin, rivaroxaban). Also excluded are those with poorly controlled hypertension, or those who have recently undergone major changes in antihypertensive therapy.\n\n2.9. Pregnant or Lactating Women: Pregnant or breastfeeding women are excluded due to potential drug transmission through the placenta or breast milk that could affect the fetus or infant.\n\n2.10. Other: Subjects who are unwilling or unable to comply with study procedures or follow-up. Any other individuals deemed unsuitable for the study at the discretion of the investigator.","35 Years","75 Years",{"count":134,"type":22},10,[136],"EARLY_PHASE1","This study aims to explore the preliminary clinical efficacy and safety of NPDR-01 eye drops in patients with non-proliferative diabetic retinopathy (NPDR).",[139,140,141,142],"Non-proliferative Diabetic Retinopathy (NPDR)","Diabetic Retinal Microangiopathy","Retinal Microaneurysms","Diabetic Retinopathy",[144,145,146],"Diabetic retinopathy","Non-proliferative diabetic retinopathy","Retinal microaneurysms","2025-09-22",{"date":149,"type":40},"2025-09-30",{"date":151,"type":22},"2025-12-01",{"date":153,"type":22},"2026-12-01",{"name":46,"class":47},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":171,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":48},"100554635","phase-4-sacubitrilvalsartan-treats-patients-with-essential-hypertension-and-type-2-diabetic-nephropathy-100554635","NCT06501651","Sacubitril\u002FValsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy","A Prospective, Randomized, Controlled, Multicenter Study of Sacubitril\u002FValsartan in the Treatment of Patients With Mild to Moderate Essential Hypertension and Type 2 Diabetic Nephropathy: The Hyper-Save Study","Hyper-Save","Inclusion Criteria:\n\n* Age 18 years or older, no gender restriction;\n* Diagnosed with mild to moderate primary hypertension (140 ≤ SBP \\\u003C 180 mmHg and\u002For 90 ≤ DBP \\\u003C 110 mmHg), including newly diagnosed or inadequately treated patients (those who have not followed previous medical advice and have uncontrolled blood pressure according to the investigator);\n* Diagnosed with type 2 diabetes (according to Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)), and meeting the following conditions: a) Continuously on ≥ 1 glucose control medication regimens (which may include long-acting insulin) for at least 12 weeks before screening, with a stable treatment regimen (i.e., the same medication and dosage) for at least 28 days before screening, and maintaining this regimen during the study. At the investigator's discretion, the dose of supplemental short-acting insulin can be adjusted as needed to achieve adequate glucose control; b) HbA1c level ≤ 10.5% and fasting (≥ 8 hours) plasma glucose level ≤ 13.3 mmol\u002FL (if fasting glucose \\> 13.3 mmol\u002FL, the investigator may repeat the test to determine eligibility);\n* Urine albumin\u002Fcreatinine ratio (UACR) ≥ 30 mg\u002Fg in two measurements taken on separate days or eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m²;\n* Non-pregnant or fertile patients (male or female) using reliable contraception;\n* Female patients with potential for pregnancy must have a negative pregnancy test at screening;\n* Subjects must voluntarily agree to comply strictly with the study protocol requirements and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Presence of severe hypertension, malignant hypertension, hypertensive emergencies, or hypertensive crises;\n* History or evidence of secondary hypertension within 12 months before screening, including but not limited to any of the following: renovascular hypertension, renal parenchymal hypertension, unilateral or bilateral renal artery stenosis, coarctation of the aorta, primary aldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension;\n* History of angioedema (drug-related or other causes) within 12 months before screening;\n* Presence of diabetic ketoacidosis;\n* History or evidence of secondary diabetes within 12 months before screening, including but not limited to any of the following: endocrine disorders causing carbohydrate metabolism disorders, pancreatogenic diabetes, hepatogenic diabetes, nephrogenic diabetes, etc.;\n* History of malignancy in any organ system (excluding localized basal cell carcinoma of the skin);\n* History of acute stroke, lacunar infarction, or dementia within 6 months before screening;\n* History of coronary artery bypass graft surgery or any percutaneous coronary intervention (PCI) within 6 months before screening;\n* Previously diagnosed or currently diagnosed heart failure (NYHA Class III-IV) or clinically significant valvular heart disease;\n* History or current diagnosis of cardiac abnormalities: (1) second or third-degree atrioventricular block without a pacemaker; (2) clinically significant arrhythmias, including atrial fibrillation with a ventricular rate ≥ 120 bpm; (3) family history of long QT syndrome or torsades de pointes ventricular tachycardia;\n* Chronic kidney disease stage 4 or higher (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²), receiving renal dialysis, or history of kidney transplantation;\n* Significant abnormalities in laboratory tests, such as potassium levels \\> 5.5 mmol\u002FL or \\\u003C 3.5 mmol\u002FL, sodium levels \\\u003C 130 mmol\u002FL, liver function (ALT, AST) results \\> 3 times the upper limit of normal;\n* History of allergy to antihypertensive drugs such as ARBs, Angiotensin-Converting Enzyme (ACE) inhibitors, or renin inhibitors;\n* Clear history of intolerance to drugs similar to the study medication (e.g., ACE inhibitors, ARBs);\n* Use of traditional Chinese or Western medicines that could affect the study's efficacy during the study period (see appendix for list);\n* Any surgery or medical condition that significantly alters the absorption, distribution, metabolism, or excretion of any medication, including but not limited to the following: clinically significant gastrointestinal surgery within 12 months before the screening (e.g., gastrectomy, gastrointestinal anastomosis, bowel resection, gastric bypass, gastroenterostomy, or gastric banding), current active inflammatory bowel disease or history of active inflammatory bowel disease;\n* Pregnant or breastfeeding women, or patients of childbearing potential unwilling or unable to use effective contraception during the study period;\n* Participation in another clinical study using any investigational drug or observational study within 30 days before screening;\n* Other conditions that, in the investigator's judgment, may affect the conduct of the clinical study or the determination of study results.",{"count":164,"type":22},297,[82],"This study aims to compare the efficacy and safety of Sacubitril\u002FValsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups, with a total of 297 eligible subjects randomly assigned in a 2:1 ratio to either the experimental group or the control group.Subjects will participate in the study through two phases: the screening period and the follow-up period.The primary outcome measure is the change in systolic blood pressure from baseline after 12 weeks of treatment.",[168,169,170],"Essential Hypertension","Type 2 Diabetes","Nephropathy",[172,173,170,174],"Essential hypertension","Type 2 diabetes","Sacubitril\u002FValsartan","2024-07-09",{"date":177,"type":40},"2024-07-15",{"date":179,"type":22},"2024-08-01",{"date":181,"type":22},"2025-04-10",{"name":46,"class":47},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":204,"locationsCount":48},"100546748","dapagliflozin-delays-the-loss-of-renal-function-in-peritoneal-dialysis-patients-100546748","NCT06398977","Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients","Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis: A Single-Center Randomized Open-Label Study","Inclusion Criteria:\n\n* Patients with PD duration between 1 month and 3 months.\n* Patients aged between 18 and 75 years.\n* Voluntary signing of informed consent.\n* Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present.\n* Daily urine output ≥ 400ml\u002Fday.\n* Stable PD prescription for one month.\n\nExclusion Criteria:\n\n* Pregnant and lactating women.\n* Patients with type 1 diabetes mellitus.\n* Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past.\n* Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT \\> 120 IU\u002FL, and other clinically confirmed severe liver diseases.\n* Patients with more than 2 episodes of urinary tract infection in the past six months.\n* Patients with severe allergic reactions (rash or angioedema) to Dapagliflozin.\n* Patients using the following medications: rifampicin, phenytoin.\n* Patients with malignant tumors.\n* Patients who developed peritonitis within one month.\n* Patients undergoing combined hemodialysis treatment.\n* Patients with a willingness for kidney transplantation within six months.\n* Patients with a history of pancreatitis or pancreatic transplantation.\n* Patients who experienced acute coronary syndrome or cerebrovascular events within one month.\n* Hemoglobin level less than 90g\u002FL.",{"count":191,"type":22},70,[25],"This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.",[195,196,197],"Peritoneal Dialysis Complication","Renal Function Aggravated","Sodium-glucose Co-transporter-2 Inhibitors","2024-04-30",{"date":200,"type":40},"2024-05-03",{"date":202,"type":40},"2024-03-11",{"date":44,"type":22},{"name":46,"class":47},""]